Dr. Sunil Nagpal, MD

Dr. Nagpal practices at Bronson Methodist Hospital in Kalamazoo, Michigan, part of Bronson Healthcare Group.

Dr. Nagpal's NPI, 1194734640, was assigned on August 5, 2006. Dr. Nagpal holds Michigan license 4301062595.

Dr. Nagpal's primary practice is Bronson Methodist Hospital, at 601 John Street, Kalamazoo, MI 49007 in Kalamazoo County. The practice phone is (269) 341-6000.

Dr. Nagpal's primary practice is Bronson Methodist Hospital in Kalamazoo, Michigan, part of Bronson Healthcare Group. Dr. Nagpal is also affiliated with Beacon Kalamazoo. The medical group on file is Bronson Medical Group. Dmand AI also links Dr. Nagpal to 3 more hospitals, 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nagpal practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Nagpal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Nagpal is licensed in Michigan.

CMS data shows 835 Medicare services from Dr. Nagpal across 7 procedure codes in 2024, for 396 Medicare patients. Medicare paid $57,017 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 396 Medicare patients who saw Dr. Nagpal in 2024. The largest group is 65 to 74, with 186 patients. 75% of them have cancer, and 64% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nagpal's median patient age at 71, with 74% women.

In 2024, Dr. Nagpal wrote 2,826 Medicare Part D claims for 548 patients. 85% of them were for generic drugs. CMS names the drug for 2,533 of them, across 42 drugs with 11 or more claims each, at $3,690,693 in total drug cost. In 2023, CMS named 2,188 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Nagpal for performance year 2024, reported as part of a group. Dr. Nagpal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nagpal as offering telehealth.

Dmand AI links 30 papers to Dr. Nagpal, published from 2011 to 2024. 2018 was the busiest year, with 5. The most frequent topics are Arthritis, Rheumatoid, Synovial Membrane and Dendritic Cells. Dr. Nagpal has published most often in JCI Insight. Dr. Nagpal's most frequent co-authors are Mark Simonds Riddle, MD, Jeremy S. Abramson, MD and Nancy Lee Bartlett, MD.

Dmand AI links Dr. Nagpal to 10 clinical trials, 8 of them phase 3 studies. 9 are still active or recruiting. Conditions studied include Breast Neoplasms, Male, Carcinoma, Intraductal, Noninfiltrating and Carcinoma, Non-Small-Cell Lung. Alliance for Clinical Trials in Oncology sponsors the most, 2.

CMS Open Payments shows 230 general payments to Dr. Nagpal from 48 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 49% of the total. Heron Therapeutics, Inc. paid the most, $7,046.